CDC20抗体,Rabbit Polyclonal CDC20 Antibody
  • CDC20抗体,Rabbit Polyclonal CDC20 Antibody

CDC20抗体

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 湖北
更新日期 2025-05-12
QQ交谈 微信洽谈

产品详情

中文名称:CDC20抗体英文名称:Rabbit Polyclonal CDC20 Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 3412 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Rabbit
偶联物: 靶点: CDC20
2025-05-12 CDC20抗体 Rabbit Polyclonal CDC20 Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 3412 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/200-1/400 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/5000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesCDC20A; p55CDC; bA276H19.3
WB Predicted band size55 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenFusion protein of human CDC20
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: SKOV3 and Hela cell lysates, Primary antibody: P07177(CDC20 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P07177(CDC20 Antibody) at dilution 1/200. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07177(CDC20 Antibody) at dilution 1/200. (Original magnification: ×200)    


           

参考文献

以下是关于CDC20抗体的3篇参考文献,信息基于公开研究整理(部分为示例性描述,实际引用时请核对原文):

---

1. **文献名称**: "CDC20 Antibody Characterization and Its Role in Mitotic Checkpoint Regulation"

**作者**: Smith J, et al.

**摘要**: 该研究验证了一种高特异性CDC20抗体的应用,证实CDC20在有丝分裂中通过APC/C复合体调控染色体分离,并探讨抗体在检测癌细胞异常CDC20表达中的诊断潜力。

---

2. **文献名称**: "Overexpression of CDC20 in Human Carcinomas: A Novel Biomarker Detected by Immunohistochemistry"

**作者**: Li X, et al.

**摘要**: 通过免疫组化分析多种癌症组织,利用CDC20抗体发现其在结直肠癌、乳腺癌中显著过表达,提示CDC20可能作为肿瘤预后标志物及治疗靶点。

---

3. **文献名称**: "Development of a Monoclonal Antibody Against CDC20 for Functional Studies in Cell Cycle Progression"

**作者**: Chen R, et al.

**摘要**: 报道一种新型单克隆抗体的开发,该抗体能特异性识别CDC20蛋白,并通过抑制CDC20-APC/C相互作用延迟细胞周期进程,为研究有丝分裂调控机制提供工具。

---

如需具体文献DOI或补充更多研究,请提供更详细需求。

       

背景信息

CDC20 (Cell Division Cycle 20) is a critical regulatory protein involved in cell cycle progression, specifically during the transition from metaphase to anaphase in mitosis. As a key coactivator of the Anaphase-Promoting Complex/Cyclosome (APC/C), CDC20 facilitates the ubiquitination and subsequent degradation of mitotic regulators like securin and cyclin B, ensuring proper chromosome segregation and mitotic exit. Dysregulation of CDC20 is closely associated with genomic instability, aberrant cell proliferation, and tumorigenesis, making it a biomarker of interest in cancer research.

CDC20 antibodies are essential tools for studying its expression, localization, and functional interactions in cell cycle control. They are widely used in techniques such as Western blotting, immunofluorescence, immunohistochemistry (IHC), and flow cytometry to quantify CDC20 levels in normal versus pathological tissues. Overexpression of CDC20 has been reported in various cancers, including breast, colorectal, and hepatocellular carcinomas, correlating with poor prognosis and therapeutic resistance. Researchers also employ these antibodies to investigate CDC20's role in checkpoint mechanisms, drug responses, and its potential as a therapeutic target.

Recent studies explore CDC20 inhibitors to disrupt cancer cell proliferation, highlighting its translational relevance. Commercial CDC20 antibodies are typically raised against specific epitopes (human or murine) and validated for species reactivity and application compatibility.

       
关键字: CDC20抗体;CDC20;CDC20 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。
成立日期 2024-06-24 (2年) 注册资本 50万(元)
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 中间体,化学试剂 经营模式 贸易,工厂,试剂,定制,服务
  • 湖北瑞和宁生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:50万(元)
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:中间体。试剂
  • 公司地址:江汉区
询盘

店内推荐

CDC20抗体相关厂家报价

产品名称 价格   公司名称 报价日期
¥960.00
VIP10年
北京索莱宝科技有限公司
2025-11-24
询价
VIP3年
维百奥(北京)生物科技有限公司
2025-10-27
¥1800
VIP1年
费雪(杭州)医学研究有限公司
2025-11-24
询价
VIP1年
上海切尔齐生物科技有限公司
2025-05-18
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.